SIDDAVARAM NAGINI¹, PRATHAP REDDY KALLAMADI², KRANTHI KIRAN KISHORE TANAGALA³, GEEREDDY BHANUPRAKASH REDDY^2,*

Oncology Research, Vol.32, No.8, pp. 1287-1308, 2024, DOI:10.32604/or.2024.049918

Abstract Aldo-keto reductases (AKRs) are a superfamily of enzymes that play crucial roles in various cellular processes, including the metabolism of xenobiotics, steroids, and carbohydrates. A growing body of evidence has unveiled the involvement of AKRs in the development and progression of various cancers. AKRs are aberrantly expressed in a wide range of malignant tumors. Dysregulated expression of AKRs enables the acquisition of hallmark traits of cancer by activating oncogenic signaling pathways and contributing to chemoresistance. AKRs have emerged as promising oncotherapeutic targets given their pivotal role in cancer development and progression. Inhibition of aldose reductase… More >

LINGLI ZHANG^1,2,#, YAN LI^1,#, JINGXIN MAO^1,*

BIOCELL, Vol.48, No.6, pp. 905-922, 2024, DOI:10.32604/biocell.2024.050396

Abstract Hepatocellular carcinoma (HCC) remains a prevalent and challenging malignancy globally, characterized by its numerous causal factors and generally unfavorable prognosis. In the relentless pursuit of effective treatment modalities, natural products have emerged as a promising and relatively non-toxic alternative, garnering significant interest. The integration of natural products with contemporary medical research has yielded encouraging therapeutic outcomes in the management of HCC. This review offers a comprehensive overview of the causal factors underlying HCC, and the diverse treatment options available, and highlights the advancements made by natural products in anti-HCC research. Particularly, we provide an outline More >

HONGBIAO WU^*, DONGFANG LIU

BIOCELL, Vol.48, No.6, pp. 971-980, 2024, DOI:10.32604/biocell.2024.049466

Abstract Background: Colorectal cancer (CRC) represents a substantial risk to public health. Bevacizumab, the first US FDA-approved antiangiogenic drug (AAD) for human CRC treatment, faces resistance in patients. The role of lipid metabolism, particularly through OPA3-regulated lipid droplet production, in overcoming this resistance is under investigation. Methods: The protein expression pattern of OPA3 in CRC primary/normal tissues was evaluated by bioinformatics analysis. OPA3-overexpressed SW-480 and HCT-116 cell lines were established, and bevacizumab resistance and OPA3 effects on cell malignancy were examined. OPA3 protein/mRNA expression and lipid droplet-related genes were measured with Western blot and qRT-PCR. OPA3… More > Graphic Abstract

Tao Xie^*, Yao Li^†, Shi-Lei Li^*, Hai-Feng Luo^‡

Oncology Research, Vol.24, No.6, pp. 447-453, 2016, DOI:10.3727/096504016X14685034103590

Abstract Although astragaloside IV exhibits anti-inflammation, immunoregulatory, and anticancer properties, the chemosensitization effects of astragaloside IV in colorectal cancer have never been reported. Our study tested whether astragaloside could increase cisplatin sensitivity in colorectal cancer. CCK-8 assay was used to measure the cell viability of colorectal cancer cells. Quantitative real-time PCR and Western blot were performed to determine the mRNA and protein expression, respectively. Our data revealed that astragaloside IV administration significantly suppressed the cell growth of colorectal cancer cells, whereas no obvious cytotoxicity of astragaloside IV was observed in nonmalignant colonic cells. In addition, combined… More >

Sheng Li, Zhengli Cui, Xianfeng Meng

Oncology Research, Vol.24, No.4, pp. 279-286, 2016, DOI:10.3727/096504016X14666990347554

Abstract Poly(ADP-ribose) polymerase 1 (PARP-1) is reported to be involved in DNA repair and is now recognized as a key regulator in carcinogenesis. However, the potential role and the molecular mechanism underlying the effect of PARP-1 on osteosarcoma (OS) cells have not been elucidated. In this study, the results showed that knockdown of PARP-1 resulted in decreased cell proliferation, increased cell apoptosis, and G₀/G₁ phase arrest in U2OS cells. In addition, increased expression of active caspase 3 and Bax, but reduced Bcl-2, cyclin D1, and phosphorylated extracellular signal regulated kinase 1/2 (pERK1/2) were observed in PARP-1 knockdown More >

Ping Chen^*, Qing Jin^*, Qiang Fu^*, Peidong You^*, Xi Jiang^*, Qin Yuan^*, Huifang Huang^†

Oncology Research, Vol.24, No.4, pp. 215-223, 2016, DOI:10.3727/096504016X14634208143021

Abstract This study aimed to investigate the role of the PI3K/Akt signaling pathway in multidrug resistance of acute myeloid leukemia (AML) cells induced by cocultured stromal cells. Human AML cell lines HL-60 and U937 were adhesion cocultured with human bone marrow stromal cell line HS-5 cells. Such coculturing induced HL-60 and U937 cells resistant to chemotherapeutic drugs including daunorubicin (DNR), homoharringtonine (HHT), and cytosine arabinoside (Ara-C). The coculturing-induced resistance of AML cells to DNR, HHT, and Ara-C can be partially reversed by inhibition of the PI3K/Akt signaling pathway. Clinically, AML patients with a low level of More >

Jiahao Su^*, Meiqin Cai^*, Wensheng Li^*, Bo Hou^†, Haiyong He^†, Cong Ling^†,Tengchao Huang^†, Huijiao Liu^†, Ying Guo^*

Oncology Research, Vol.24, No.2, pp. 117-128, 2016, DOI:10.3727/096504016X14612603423511

Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis. Temozolomide plus radiotherapy (TEM+RAD) is the most common treatment for newly diagnosed GBM. With the development of molecularly targeted drugs, several clinical trials were reported; however, the efficacy of the treatment remains controversial. So we attempted to measure the dose of the molecularly targeted drug that could improve the prognosis of those patients. The appropriate electronic databases (PubMed, MEDLINE, EMBASE, and the Cochrane Library) were searched for relevant studies. A meta-analysis was performed after determining which studies… More >

Kazuyoshi Kawakami^*, Takashi Yokokawa^*, Kazuo Kobayashi^*, Takahito Sugisaki^*, Kenichi Suzuki^*, Mitsukuni Suenaga^†, Kensei Yamaguchi^†, Ayaka Inoue^‡, Yoshiaki Machida^‡, Toshiharu Yamaguchi^†, Toshihiro Hama^*

Oncology Research, Vol.25, No.9, pp. 1625-1631, 2017, DOI:10.3727/096504017X15012905098071

Abstract Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011, and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study assessed adherence… More >

Angelica Perna^*†, Angela Lucariello^*†, Carmine Sellitto^*, Iolanda Agliata^†, Maria Aurora Carleo^‡, Vincenzo Sangiovanni^‡, Vincenzo Esposito^§, Germano Guerra^†, Luigi Cobellis^¶, Antonio De Luca^*

Oncology Research, Vol.25, No.9, pp. 1617-1624, 2017, DOI:10.3727/096504017X14905635363102

Abstract Antiretroviral drugs used for the treatment of human immunodeficiency virus (HIV) have proven to be effective even against cancer. Drawing from this background, the aim of our research project was to evaluate the effects of anti-HIV drugs that belong to the nucleoside and nucleotide reverse transcriptase inhibitor [NRTI; abacavir (ABC) and tenofovir (TDF)], nonnucleoside reverse transcriptase inhibitor [NNRTI; efavirenz (EFV) and etravirine (ETR)], and protease inhibitor [PI; darunavir (DRV)] categories on ovarian adenocarcinoma cell line SKOV-3. Using FACS analysis, we observed that treatment with NRTIs and NNRTIs showed a block in the G₀/G₁ phase. In particular,… More >

Xin Jin^*, Shenghua Tian^†, Pingping Li^‡

Oncology Research, Vol.25, No.6, pp. 939-946, 2017, DOI:10.3727/096504016X14809827856524

Abstract Hepatocellular carcinoma (HCC) is one of the most common malignant diseases in the world. Mutations, overexpression, and improper recruitment of HATs can lead to tumorigenesis. HAT1 is the first histone acetyltransferase identified and is related with developing HCC, but the mechanism is still unclear. Interestingly, we found that HAT1 was upregulated in HCC patient specimens and showed that its upregulation facilitates HCC cell growth in vitro and in vivo. Moreover, we demonstrated that HAT1 promoted glycolysis in HCC cells and knockdown of HAT1 sensitized HCC cells to apoptotic death induced by cisplatin. Our results suggest More >